Pfizer's phase 3 maternal RSV vaccine trial hits at interim review, prompting early stop and race to FDA Lilly powers through final stretch in critical Alzheimer's race BioCryst leaves ultra-rare bone disease efforts in hands of Ipsen, Regeneron with discontinuation Lilly gives up on $40M BCL-2 buy as part of latest pipeline cull Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out Arch-backed HI-Bio launches with 2 clinical-stage therapies from MorphoSys and $120M in cash Newly refocused Unity's ophthalmology asset improves vision in phase 2 | 